FDA Brief

Warning letters Drugs

FDA warning letter to

Organic Heirloom Plants

High riskIssued Jan 30, 2023Posted Jan 31, 2023Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Organic Heirloom Plants over selling unapproved drugs with claims to treat mpox, cancer, diabetes and other diseases.

What happened

In October 2022, FDA reviewed the company's website, promotional literature, and Facebook page. FDA found claims that Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature's Ancer, Ivermectwin, Zeolite, and Chaga Mushroom cure, mitigate, treat, or prevent diseases including mpox, cancer, COPD, HIV, and diabetes. FDA said these are unapproved new drugs—products sold for drug uses without FDA approval—and misbranded drugs.

What FDA found

  1. The company's website, promotional literature, and Facebook posts show the products are intended to cure, mitigate, treat, or prevent diseases.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and are sold without FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. 355(a)]
  3. The products are misbranded because they do not bear adequate directions for use by a layperson for diseases that require licensed practitioner supervision.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. The products are also misbranded drugs under section 502.

    Section 502 of the Act [21 U.S.C. 352]
  5. Introducing the misbranded drugs into interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, FDA asks the company to notify it in writing of specific steps taken to correct the violations, including preventive steps and documentation, or to explain why correction will take longer and when it will be completed. FDA also requests that the company cease sale of any unapproved products claiming to mitigate, prevent, treat, diagnose, or cure mpox.

Who should pay attention

  • online sellers of herbal and supplement products
  • companies that make disease-treatment claims on websites or social media
  • quality and regulatory teams reviewing promotional claims and search metatags

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk